timothy sykes logo
BIAF Stock Pops As Federal Lung Test Deal Fuels Momentum Thumbnail
G Google News

BIAF Stock Pops As Federal Lung Test Deal Fuels Momentum

TIM SYKES•UPDATED SEP. 3, 2026, 9:20 AM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

bioAffinity Technologies Inc. stocks have been trading up by 34.58 percent amid heightened optimism from its latest cancer diagnostics developments

Key Takeaways

  • Nationwide AvMEDICAL deal gives BIAF access to VA and other federal healthcare systems, a major commercial door-opener for CyPath Lung.
  • Q2 2026 showed explosive CyPath Lung growth, with test volume up 216% and physician accounts up 122%, pushing total revenue to $1.5M.
  • Despite progress, BIAF remains deeply unprofitable, running with limited cash, recent equity raises, and ongoing Nasdaq delisting risk.
  • Management is moving CyPath Lung beyond early detection into survivor surveillance, targeting recurrence monitoring alongside imaging.
  • EPS loss improved to -$0.64 from -$5.07 year over year as revenue and clinical confidence in BIAF’s CyPath Lung test climbed.

Candlestick Chart

Live Update At 09:18:43 EDT: On Thursday, September 03, 2026 bioAffinity Technologies Inc. stock [NASDAQ: BIAF] is trending up by 34.58%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

BIAF has been trading like a classic low-float biotech momentum name. On 2026/09/02, BIAF ripped from a $7.61 open to an $11.75 high before closing at $9.75. That follows a run from sub-$1 levels in mid‑August, when BIAF was closing around $0.40–$0.47. For traders, that’s a massive percentage move in just a couple of weeks, the kind of volatility that can create both big wins and brutal losses.

The intraday tape shows BIAF holding the $10–$14 zone with sharp swings, a sign of active day trading and short‑term speculation. This kind of price action often follows a news and fundamentals shift, which we’re seeing in BIAF’s recent reports.

More Breaking News

Fundamentally, BIAF booked $1.5M in Q2 2026 revenue, up from $1.27M a year earlier, driven almost entirely by CyPath Lung. The company’s gross margin sits above 50%, but operating losses are still heavy, with Q2 net loss at about $3.37M and EBITDA around -$3.29M. Cash at period‑end was roughly $2.4M, only partially shored up by a $3.2M equity raise. For traders, that mix—strong top‑line growth, tight cash, and equity financing—puts dilution, volatility, and headline risk front and center on BIAF.

Why Traders Are Watching BIAF Right Now

BIAF is finally acting like a real growth story, not just a biotech on life support. The core driver is CyPath Lung, the company’s noninvasive sputum‑based lung cancer diagnostic. In Q2 2026, BIAF reported CyPath Lung test volume up 216% year over year. Physician accounts jumped 122%, and existing customers increased orders by 71%. Those are the kind of acceleration numbers momentum traders hunt for.

Revenue is still small in absolute terms—first‑half 2026 CyPath Lung sales were about $0.8M—but the trajectory is the key. BIAF’s total Q2 revenue hit $1.5M, a 19% increase, with EPS loss improving to -$0.64 from a brutal -$5.07 a year earlier. The company is far from breakeven, yet the direction of travel is improving.

Then there’s the federal angle. BIAF signed a nationwide distribution agreement with AvMEDICAL to push CyPath Lung into U.S. government systems, including the Department of Veterans Affairs. That puts BIAF in front of VA and other federal healthcare buyers through established IDIQ contracting and a government‑focused sales force. For traders, this is a genuine step‑change setup: if execution is solid, CyPath Lung volumes could scale sharply among veterans and federal beneficiaries.

BIAF is also expanding the CyPath Lung story beyond early detection. The company is positioning the test for post‑treatment surveillance of lung cancer survivors, aiming to complement imaging for recurrence and new primary cancers. Add in a VA‑ and military‑backed longitudinal trial plus pipeline work in asthma/COPD diagnostics and topical siRNA skin cancer therapeutics, and BIAF starts to look like a broader precision‑medicine platform. That optionality is exactly what keeps speculative traders glued to the chart.

Conclusion

BIAF sits at an interesting crossroads: strong operational momentum colliding with real financial strain. On the positive side, CyPath Lung is gaining traction fast, with BIAF showing rapid growth in test volumes, physician accounts, and repeat orders. The AvMEDICAL distribution deal gives BIAF a clear pathway into VA and federal systems, and new use cases in survivor surveillance could deepen adoption over time.

On the risk side, BIAF is still heavily loss‑making, posting a Q2 net loss of roughly $3.37M on just $1.5M in revenue. The balance sheet is thin, with about $2.4M in cash at 2026/06/30 and dependence on equity raises—like the recent $3.2M raise—to keep the lights on. Nasdaq delisting risk hangs over BIAF as well, which often means ongoing dilution and headline shocks.

For active traders, that mix creates both opportunity and danger. BIAF’s chart shows how fast a name like this can run once news, volume, and a tight float line up, but the same factors can turn against late chasers. As Tim Sykes likes to say, “Volatile penny stocks are the best teachers — if you respect the rules, cut losses quickly, and never confuse a hot chart with guaranteed profits.” As millionaire penny stock trader and teacher Tim Sykes says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” BIAF is a live case study in that mindset, and anyone trading it should treat it as a speculative, high‑risk educational setup, not a long‑term sure thing.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”